Overview

Treatment Use Study for Advanced Melanoma.

Status:
No longer available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.

Details

Lead Sponsor:

Pfizer

Treatments:

Antibodies, Monoclonal
Tremelimumab